Donegal Group Inc. (NASDAQ:DGIC.A) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Most readers would already be aware that Donegal Group's (NASDAQ:DGIC.A) stock increased significantly by 36% over the past three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. Particularly, we will be paying attention to Donegal Group's ROE today.
Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
We've discovered 1 warning sign about Donegal Group. View them for free.
The formula for ROE is:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
So, based on the above formula, the ROE for Donegal Group is:
12% = US$70m ÷ US$585m (Based on the trailing twelve months to March 2025).
The 'return' is the profit over the last twelve months. That means that for every $1 worth of shareholders' equity, the company generated $0.12 in profit.
View our latest analysis for Donegal Group
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
To start with, Donegal Group's ROE looks acceptable. Further, the company's ROE is similar to the industry average of 13%. As you might expect, the 17% net income decline reported by Donegal Group is a bit of a surprise. Based on this, we feel that there might be other reasons which haven't been discussed so far in this article that could be hampering the company's growth. These include low earnings retention or poor allocation of capital.
However, when we compared Donegal Group's growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 14% in the same period. This is quite worrisome.
Earnings growth is a huge factor in stock valuation. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Donegal Group is trading on a high P/E or a low P/E, relative to its industry.
With a high three-year median payout ratio of 92% (implying that 8.0% of the profits are retained), most of Donegal Group's profits are being paid to shareholders, which explains the company's shrinking earnings. The business is only left with a small pool of capital to reinvest - A vicious cycle that doesn't benefit the company in the long-run.
Moreover, Donegal Group has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth.
Overall, we have mixed feelings about Donegal Group. While the company does have a high rate of return, its low earnings retention is probably what's hampering its earnings growth. That being so, the latest industry analyst forecasts show that analysts are forecasting a slight improvement in the company's future earnings growth. The company's existing shareholders might have some respite after all. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Wall Street Climbs, Oil Slides Following Israel-Iran Ceasefire
Equities rallied Tuesday, while oil prices retreated as markets responded to a US-brokered ceasefire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00. The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year. A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the '1290 compound, with the potential to differentiate from competitors. Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company's pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
32 minutes ago
- Yahoo
Truist Financial Lowers PT on LendingTree (TREE) to $60, Retains a Buy Rating
LendingTree, Inc. (NASDAQ:TREE) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on May 5, Youssef Squali from Truist Financial maintained a Buy rating on LendingTree, Inc. (NASDAQ:TREE), lowering the firm's price target to $60 from $72. The rating update came after the company reported 'mixed' fiscal Q1 2025 results and guidance. A happily married couple discussing the merits of different home equity loan options. Truist Financial expressed optimistic sentiments for the stock, stating that factors like LendingTree, Inc.'s (NASDAQ:TREE) well-diversified revenue base, scale, and valuation make it a lucrative play amid the ongoing recovery in Insurance. The analyst told investors in a research note that the firm also expects the Home and Consumer segment to undergo recovery over time as rates normalize. LendingTree, Inc.'s (NASDAQ:TREE) balance sheet is another factor supporting the positive rating, as it is adequate to support the current business, according to the analyst. LendingTree, Inc. (NASDAQ:TREE) operates an online loan marketplace for consumers looking for loans and other credit-based offerings. The company's operations are divided into three segments: Home, Consumer, and Insurance. While we acknowledge the potential of TREE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.